These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2006-002769-38 A MULTICENTER PHASE II STUDY TO EVALUATE ACTIVITY AND TOLERABILITY OF CISPLATIN (CDDP) AND FOTEMUSTINE (FTM) COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES. not-yet-due
Ongoing 2006-002887-25 Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM). not-yet-due
Ongoing 2006-002934-40 RANDOMIZED PHASE II TRIAL OF FIRST LINE CISPLATIN WITH DOCETAXEL OR VINORELBINE FOR 6 CYCLES IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER not-yet-due
Ongoing 2006-002935-25 multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy. not-yet-due
Ongoing 2006-003270-95 Xelox-2 in untreated patients with advanced colorectal cancer.A Phase II multicenter study of the gruppo oncologico dell Italia meridionale GOIM not-yet-due
Ongoing 2006-007089-12 Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women not-yet-due
Ongoing 2007-003156-11 Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M. not-yet-due
Not reported 2009-014041-81 Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program) 2015-05-31 due-trials
Ongoing 2009-016487-36 Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM) not-yet-due
Ongoing 2009-017083-16 A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer not-yet-due
Ongoing 2010-022091-31 Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study. not-yet-due
Other 2011-006176-39 Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter random... not-yet-due
Ongoing 2012-000393-35 a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 negative metastatic breast cancer (MBC) not-yet-due
Ongoing 2012-001325-28 non-Pegylated liposomal doxrubicina (Myocet) + cyclophosphamide versus non pegylated liposomal doxorubicin (Myocet) + metronomic cyclophosphamide in metastatic breast cancer-a multicenter randomized p... not-yet-due
Not reported 2012-004126-17 Cisplatin and capecitabine (ECX) in stomach adenocarcinoma()tratment in advanced stage.Multicenter randomized phase II trial foolwed by GOIM. 2015-10-30 due-trials